Cargando…

SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association

Detalles Bibliográficos
Autores principales:	Kim, Han Sun, Kim, Doyeon, Kim, Jiwoo, Park, Sunghyouk, de Guzman, Arvie Camille V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307990/ https://www.ncbi.nlm.nih.gov/pubmed/37381167 http://dx.doi.org/10.1002/ctm2.1311

Ejemplares similares

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
por: Termini, Christina M., et al.
Publicado: (2023)

Targeting MTHFD2 in acute myeloid leukemia
por: Pikman, Yana, et al.
Publicado: (2016)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022
por: Bouligny, Ian M., et al.
Publicado: (2023)

Ferroptosis-related gene signature predicts the clinical outcome in pediatric acute myeloid leukemia patients and refines the 2017 ELN classification system
por: Tao, Yu, et al.
Publicado: (2022)

A Novel Splice-Site Mutation in the ELN Gene Suggests an Alternative Mechanism for Vascular Elastinopathies
por: Velandia-Piedrahita, Camilo Andres, et al.
Publicado: (2020)

Experiences with a researcher-centric ELN
por: Badiola, Katrina A., et al.
Publicado: (2015)

The New ELN Recommendations for Treating CML
por: Hehlmann, Rüdiger
Publicado: (2020)

Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
por: Tsai, Cheng-Hong, et al.
Publicado: (2019)

TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently
por: Kim, Han Sun, et al.
Publicado: (2023)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Institutional ELN/LIMS deployment: Highly customizable ELN/LIMS platform as a cornerstone of digital transformation for life sciences research institutes
por: Argento, Nicolas
Publicado: (2020)

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2020)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Association of Maternal Folate Intake and Offspring MTHFD1 and MTHFD2 Genes with Congenital Heart Disease
por: Liu, Hanjun, et al.
Publicado: (2023)

How I treat obesity and obesity related surgery in patients with chronic myeloid leukemia: An outcome of an ELN project
por: Yassin, Mohamed A., et al.
Publicado: (2021)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients
por: Wang, Xiaoning, et al.
Publicado: (2023)

MTHFD2- a new twist?
por: Tedeschi, Philip M., et al.
Publicado: (2016)

Binding Modes of Xanthine‐Derived Selective Allosteric Site Inhibitors of MTHFD2
por: Jha, Vibhu, et al.
Publicado: (2023)

What is VaxEln really like?: a user's view
por: Burkimsher, Paul C
Publicado: (1985)

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
por: Bonagas, Nadilly, et al.
Publicado: (2022)

Inhibition of IRE1α RNase activity sensitizes patient‐derived acute myeloid leukaemia cells to proteasome inhibitors
por: Creedican, Stuart, et al.
Publicado: (2022)

MTHFD1 controls DNA methylation in Arabidopsis
por: Groth, Martin, et al.
Publicado: (2016)

Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia
por: Khan, Ghazala Naz, et al.
Publicado: (2019)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Subnuclear physics: the first 50 years, highlights from Erice to ELN
por: Zichichi, A, et al.
Publicado: (2000)

Subnuclear physics: the first fifty years, highlights from Erice to ELN
por: Zichichi, Antonino, et al.
Publicado: (1998)

openBIS ELN-LIMS: an open-source database for academic laboratories
por: Barillari, Caterina, et al.
Publicado: (2016)

Chemotion ELN: an Open Source electronic lab notebook for chemists in academia
por: Tremouilhac, Pierre, et al.
Publicado: (2017)

Emerging Role of Edible Exosomes-Like Nanoparticles (ELNs) as Hepatoprotective Agents
por: Subudhi, P. Debishree, et al.
Publicado: (2022)

ELN missense variant in patient with mid-aortic syndrome case report
por: Phan, Thao Nguyen, et al.
Publicado: (2022)

AI4Green: An Open-Source ELN for Green and Sustainable Chemistry
por: Boobier, Samuel, et al.
Publicado: (2023)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

The First Structure of Human MTHFD2L and Its Implications for the Development of Isoform‐Selective Inhibitors
por: Scaletti, Emma R., et al.
Publicado: (2022)

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities
por: Chilton, L, et al.
Publicado: (2016)

Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease
por: Tavarozzi, Rita, et al.
Publicado: (2021)

Donor‐transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation
por: Ghandili, Susanne, et al.
Publicado: (2022)

Targeting Apoptotic Pathways in Acute Myeloid Leukaemia
por: Sillar, Jonathan R., et al.
Publicado: (2019)

Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits
por: Hilal, Talal
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4leuse305a1qeurpba4ejsasf1